News

Keynote address at the 22nd Annual Neuroscience Zappulla Research Day

June 3, 2026

I was honored to be delivering the keynote address at the 22nd Annual Neuroscience Zappulla Research Day on Wednesday, June 3, at the Hackensack Meridian Neuroscience Institute, JFK University Medical Center in Edison, NJ.

My lecture: "Treatment of Refractory Migraines — What to Do When 'Nothing Works'." This is the question I hear most often from patients who have tried medication after medication, from neurologists who have exhausted standard protocols, and from families watching someone they love suffer without answers. The truth is, "nothing works" is rarely accurate. It usually means the right approach hasn't been found yet. That's what I discussed with colleagues who are advancing this field.

Written by
Alexander Mauskop, MD
Continue reading
May 26, 2026
News
Why I Rarely Prescribe Topiramate, and What the New Data Shows
A new real-world study of 661 patients found that 67% stopped taking topiramate within six months, compared to 30% on candesartan. Candesartan also had a higher responder rate. Topiramate is FDA-approved; candesartan is not. The data makes the case for rethinking that priority.
Read article
May 21, 2026
Research
Your Brain Has Many Pathways, And TMS Can Now Use Them
A groundbreaking University of Iowa study shows that personalized fMRI-guided TMS can now reach and modulate the deep hippocampus — the brain’s command center for memory, emotion, and migraine — without surgery or heavy medications. By mapping each patient’s unique neural pathways, TMS delivers precise stimulation to surface “control points” that influence deep brain structures. Generic approaches barely work, but individualized targeting produces clear, measurable changes. At our headache clinic, we combine TMS and fMRI to offer this advanced, personalized treatment for migraines, depression, PTSD, anxiety, and more.
Read article
May 10, 2026
Research
Elismetrep: A Promising New Experimental Migraine Treatment
Elismetrep is a promising experimental migraine medication that targets the TRPM8 pathway rather than serotonin or CGRP. Early clinical trials suggest it may offer a new option for patients who do not respond well to current treatments.
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe